Esperion to Participate in The Citizens Life Sciences Conference

Rhea-AI Summary

Esperion (NASDAQ: ESPR) has announced its participation in the upcoming Citizens Life Sciences Conference scheduled for May 8, 2025, at 12:30 p.m. ET. The event will be webcasted and accessible through Esperion's website, with replay available for approximately 90 days.

Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.

The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion aims to expand globally through commercial execution, international partnerships, and pre-clinical pipeline advancement.

ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.

Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

When and what time is Esperion (ESPR) presenting at the Citizens Life Sciences Conference?

Esperion (ESPR) will present at the Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET.

How long will the webcast replay be available on Esperion's website?

The webcast replay will be archived on Esperion's website for approximately 90 days after the event.

What distinguishes Esperion's cardiovascular medications in the market?

Esperion offers the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk.

What is Esperion's next-generation drug development program focused on?

Esperion's next-generation program focuses on developing ATP citrate lyase inhibitors (ACLYi) with highly potent and specific inhibitors using allosteric mechanisms.

How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?

The CLEAR Cardiovascular Outcomes Trial included nearly 14,000 patients.